Clinical Trial

Azenta Announces Collaboration with the Crohn’s & Colitis Foundation to Support its Crohn’s Disease and Ulcerative Colitis Clinical Research

Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel…

2 months ago

MetaDeq Diagnostics Announces Two Abstracts to be Presented at the EASL International Liver Congress™

HeparDx™ is an investigational MASH (NASH) activity and liver fibrosis blood test designed to diagnose and stage patients, detect at-risk…

2 months ago

Intermountain Health and CareCentra expand partnership to launch AI-led innovation to combat COPD and Asthma hospitalizations

NEW YORK, June 4, 2024 /PRNewswire/ -- Intermountain Health has expanded its agreement and partnership with CareCentra, Inc., to include…

2 months ago

Leal Health to Unveil New Data on Benefits of Digital Health for Bridging Cancer Care Gaps at 2024 ASCO Annual Meeting

Data Will Show How Digital Health Platforms Increase Access to Care for Diverse Patient Populations NEW YORK, June 4, 2024…

2 months ago

Ryght and University of Adelaide Announce Strategic Partnership at BIO

The collaboration will help establish South Australia as a global leader in AI and biotechnology. LAGUNA BEACH, Calif., June 4,…

2 months ago

Masdar City to Showcase Its Life Sciences Hub at BIO24 in San Diego

Masdar City to showcase why they are the leading destination for the life sciences sector at BIO24 ABU DHABI, UAE,…

2 months ago

Nalu PNS System Achieves Significant and Durable Pain Reduction, Meeting the Primary Endpoint of the COMFORT RCT Study

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical Inc. (“Nalu”) revealed significant findings from a landmark clinical trial evaluating the Nalu Peripheral Nerve Stimulation…

2 months ago

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to…

2 months ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

2 months ago